We examined the direct effects of human recombinant interleukin 2 (hrIL-2) in vitro on the phenotypic and the functional changes of rat Kupffer cells (KCs) isolated by collagenase perfusion and differential centrifugation. When KCs were cultured with high concentrations of hrIL-2, marked changes were dose-dependently observed in phenotypic expression, phagocytic activity, and accessory cell function compared to untreated KCs. In the phenotypic changes, approximately 70% of KCs expressed class 2 antigen after 48-hr culture. Moreover, rapid expression of iC3b receptor on KCs was observed after 6 hr culture. KC phagocytic activity of both 0.81-and 2-μm latex particles was increased by incubating with hrIL-2 (104 U/ml) as compared to those of untreated KCs. Complement-mediated phagocytosis was more dominant than that of Fc receptor-mediated phagocytosis without hrIL-2 and augmented by increasing concentrations of hrIL-2. Accessory cell function of KCs was greatly augmented by preincubation with hrIL-2 (104 U/ml) for 24 hr. In the presence of 10−6 M of indomethacin or prostaglandin E2, accessory cell function was at a lower level than without. This suppressive effect of indomethacin or prostaglandin E2 was reduced at lower concentrations. These results suggest that the potential ability of hrIL-2-activated KCs is closely associated with the ongoing pathophysiological process in the liver during IL-2 immunotherapy.
1. Anderson TD and Hayes TJ (1989). Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement. Lab. Invest60: 331–346.
2.
2. Aronson FR, Libby P, Brandon EP, Janicka MW, and Mier JW (1988). IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J. Immunol141: 158–163.
3.
3. Blay JY, Bertoglio J, Fradelizi D, and Chouaib S (1989). Functional interactions of IL-2 and TNF in the differentiation of LGL into LAK effectors. Int. J. Cancer44: 598–604.
4.
4. Chang AE, Hyatt CL, and Rosenberg SA (1984). Systemic administration of recombinant human interleukin-2 in mice. J. Biol. Response Mod3: 561–572.
5.
5. Curran RD, Billiar TR, West MA, Bentz BG, and Simmons RL (1988). Effect of interleukin-2 on Kupffer cell activation. Interleukin-2 primes and activates Kupffer cells to suppress hepatocyte protein synthesis in vitro. Arch. Surg123: 1373–1378.
6.
6. Decker K (1990). Review: Biologically active products of stimulated liver macrophages (Kupffer cells). Eur. J. Biochem192: 245–261.
7.
7. Decker T, Lohmann-Matthes M-L, Karck U, Peters T, and Decker K (1989). Comparative study of cytotoxicity, tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cells, murine Kupffer cells, and murine inflammatory liver macrophages. J. Leukoc. Biol45: 139–146.
8.
8. Economou JS, McBride WH, Essner R, Rhoades K, Golub S, Holmes EC, and Morton DL (1989). Tumour necrosis factor production by IL-2 activated macrophages in vitro and in vivo. Immunology67: 514–519.
9.
9. Gaillard T, Mulsch A, Busse R, Klein H, and Decker K (1991). Regulation of nitric oxide production by stimulated rat Kupffer cells. Pathobiology59: 280–283.
10.
10. Goodwin JS and Webb DR (1980). Regulation of the immune response by prostaglandins. Clin. Immunol. Immunopathol15: 106–122.
11.
11. Hancock WW, Muller WA, and Cotran RS (1987). Interleukin-2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and monocyte cell lines. J. Immunol138: 185–191.
12.
12. Herrmann F, Cannistra SA, Levine H, and Griffin JD (1985). Expression of interleukin-2 receptors and binding of interleukin-2 by gamma interferon-induced human leukemic and normal monocytic cells. J. Exp. Med162: 1111–1116.
13.
13. Holter W, Grunow R, Stockinger H, and Knapp W (1986). Recombinant interferon-gamma induces interleukin-2 receptors on human peripheral blood monocytes. J. Immunol136: 2171–2175.
14.
14. Latocha G, Dieter P, Schulze-Specking A, and Decker K (1989). Fc receptors mediate prostaglandin and superoxide synthesis in cultured rat Kupffer cells. Biol. Chem. Hoppe. Seyler370: 1055–1061.
15.
15. Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, and Rosenberg SA (1987). In vivo administration of purified human interleukin-2 to patients with cancer. Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res47: 2188–2195.
16.
16. Matory YL, Chang AE, Lipford EH, Braziel R, Hyatt CL, and Rosenberg SA (1987). The toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J. Natl. Med. Assoc79: 537–541.
17.
17. Metzger Z, Hoffeid JT, and Oppenheim JJ (1980). Macrophage-mediated suppression. I. Evidence for a participation of both hydrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation. J. Immunol124: 983–988.
18.
18. Mier JW, Brandon EP, Libby P, Janicka MW, and Aronson FR (1989). Activated endothelial cells resist lymphokine activated killer cell mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J. Immunol143: 2407–2414.
19.
19. Nagakawa J, Hishinuma I, Hirota K, Miyamoto K, Yamanaka T, Tsukidate K, Katayama K, and Yamatsu I (1990). Involvement of tumor necrosis factor-α in the pathogenesis of activated macrophage-mediated hepatitis in mice. Gastroenterology99: 758–765.
20.
20. Rogoff TM and Lipsky PE (1979). Characterization of isolated guinea pig Kupffer cells: Accessory cell function in mitogen-induced T lymphocyte activation. J. Immunol123: 1920–1927.
21.
21. Rosenberg SA, Lotze MT, Muul LM, Change AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, and White DE (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med316: 889–897.
22.
22. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, and Reichert CM (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med313: 1485–1492.
23.
23. Shiratori Y, Okano K, Matsumoto K, and Murao S (1984). Antigen presentation by Kupffer cells in the rat. Scand. J. Gastroenterol19: 733–739.
24.
24. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, and Fefer A (1988). Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J. Clin. Oncol6:669–678.
25.
25. Williams TJ and Peck MI (1977). Role of prostaglandin mediated vasodilation in inflammation. Nature (London)270: 530–532.
26.
26. Yamashita A, Hattori Y, Kotani M, Miyasaka M, and Fukumoto T (1990). A novel monoclonal antibody, Mar 1, directed specifically against mononuclear phagocyte system cells in rats. Immunology70: 262–271.
27.
27. Zhang SR, Salup RR, Unas PE, Twilley TA, Talmadge JE, Herberman RB, and Wiltrout RH (1986). Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin-2. Cancer Immunol. Immunother21: 19–25.
